Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Roche Launches Upgraded cobas 6800/8800 Systems 2.0 with CE Certification

NextEdge Admin

15 Dec 2024

2 min 6 sec

molecular diagnostics,CE certification,PCR

Roche has achieved CE certification for the upgraded cobas 6800/8800 systems 2.0, advancing molecular diagnostics with improved laboratory efficiency. The update optimizes resource use, minimizes downtime, consolidates test menus, and enhances throughput, streamlining workflows for healthcare professionals and patients.

“This update marks a significant milestone for Roche,” said Matt Sause, CEO of Roche Diagnostics. “Building on our leadership in automated molecular testing, this innovation combines exceptional throughput with the flexibility laboratories need to serve physicians and patients effectively.”

The cobas test menu, now incorporating Roche’s advanced Temperature-Activated Generation of Signal (TAGS) technology, is largely available with the update. TAGS allows simultaneous detection of up to 15 targets in a single patient sample across the cobas 5800, 6800, and 8800 systems, expanding diagnostic capabilities.

Targeting mid-to-high volume molecular testing laboratories, the cobas 6800/8800 systems address key operational challenges with intelligent workflows, high throughput, proven reliability, and flexibility. The systems also unify the user experience with innovations introduced in the cobas 5800 system.

The enhanced cobas portfolio represents Roche’s commitment to advancing PCR technology and meeting evolving laboratory needs. The company plans to submit for FDA 510(k) clearance in 2025.

Founded in 1896 in Basel, Switzerland, Roche has grown into the world’s largest biotechnology company and a global leader in in-vitro diagnostics.